Voyager Therapeutics (VYGR): Strong Q3 Prompts Bullish Coverage

Voyager Therapeutics, Inc. (NASDAQ:VYGR) is one of the Best Micro-Cap Stocks to Invest in According to Analysts.

Voyager Therapeutics (VYGR): Strong Q3 Prompts Bullish Coverage

On November 12, HC Wainwright lowered the price target on Voyager Therapeutics, Inc. (NASDAQ:VYGR) to $25 from $30 and kept a Buy rating on the shares. Per the analyst, Voyager reported strong Q3 results, ending the quarter with $229M in cash and operational runway into 2028, while remaining eligible for up to $2.4B in partner milestones.

Voyager Therapeutics, Inc. (NASDAQ:VYGR) recently presented at the Biopharma Back to School Conference organized by investment firm Citi, providing important updates to drugs under development. In earnings for the third quarter of 2025, released in early November, the firm reported losses per share of $0.47, beating analyst expectations by $0.05. The revenue over the period was in excess of $13 million, down close to 45% compared to the revenue over the same period last year and beating market estimates by $5.5 million.

Voyager Therapeutics, Inc. (NASDAQ:VYGR) is a biotechnology company that focuses on human genetics for the cure of neurological diseases.

While we acknowledge the potential of VYGR as an investment, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and have limited downside risk. If you are looking for an AI stock that is more promising than VYGR and that has a 100x upside potential, check out our report about the cheapest AI stock.

READ NEXT: 15 Dividend Stocks Paying 4%+ Yield in 2025 and 14 Best US Stocks to Buy for Long Term

Disclosure: None.